Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Predictors of outcomes to allogeneic hematopoietic cell transplantation (allo-HCT) for TP53 mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) patients and impact of hypomethylating agent (HMA) maintenance therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

HEHany ElmariahNTNancy Torres

Discussion

Loading...

Member takes

Overview

Retrospective analysis finds hypomethylating agent maintenance improves outcomes in TP53 mutant MDS and AML post-transplant.

Key Points

  • To identify predictors of survival outcomes for TP53 mutant MDS and AML patients receiving allo-HCT and the impact of HMA maintenance therapy.
  • Retrospective analysis of TP53 mutant MDS/AML patients undergoing allo-HCT from May 2014 to December 2023
  • Evaluated baseline demographics, disease type, and clinical variables
  • Focused on survival outcomes with and without hypomethylating agent maintenance
  • Median overall survival for the cohort was 18 months, with 22% alive at 5 years
  • HMA maintenance significantly improved overall survival to 32 months compared to 10 months without it
  • Cytogenetic abnormalities post-HCT were predictive of inferior survival outcomes

Cite This Study

Elmariah et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d60chttps://doi.org/10.1182/blood-2025-4291
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT2025 · 1 citations
  2. 2Outcomes of allogeneic hematopoietic cell transplant (HCT) in patients with TP53-altered acute leukemia or myelodysplastic syndrome: A retrospective single center analysis2025
  3. 3Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database2025
  4. 4Multi-hit TP53 mutation is an independent adverse prognostic factor in allogeneic hematopoietic stem cell transplantation for acute leukemia and myelodysplastic syndromes2025
  5. 5Clinical outcomes of <i>TP53</i> -mutated myeloid neoplasms after allogeneic hematopoietic cell transplantation: A Canadian multicenter propensity score–matched analysis.2026